N Marx, D Walcher, N Ivanova, K Rautzenberg, … - Diabetes, 2004 - Am Diabetes Assoc Advanced glycation end products (AGEs) are critically involved in atherogenesis
in diabetes by binding to receptors for AGE (RAGEs) in vascular cells, thus
inducing the expression of proinflammatory mediators. In animal models, ... Cited by 69 - Related articles - BL Direct - All 4 versions
- ►aspetjournals.org K Wang, Z Zhou, M Zhang, L Fan, F Forudi, X … - Journal of Pharmacology and Experimental …, 2006 - ASPET Diabetes is associated with an increase in circulating advanced glycosylation
end products (AGEs) and the increased expression of the receptor for AGEs
(RAGE). Inhibition of AGE/RAGE binding through the administration of ... Cited by 33 - Related articles - BL Direct - All 6 versions
JM Forbes, SR Thorpe, V Thallas-Bonke, J … - Journal of the American Society of Nephrology, 2005 - Am Soc Nephrol Recent studies have identified that first-line renoprotective agents that
interrupt the renin-angiotensin system not only reduce BP but also can attenuate
advanced glycation end product (AGE) accumulation. This study used in ... Cited by 72 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org AC Calkin, JM Forbes, CM Smith, M Lassila, … - Arteriosclerosis, thrombosis, and vascular biology, 2005 - Am Heart Assoc Methods and Results— Control and diabetic apolipoprotein E–deficient mice
received rosiglitazone or placebo. Diabetic mice demonstrated a 3-fold increase
in plaque area, which was attenuated by rosiglitazone. There was no ... Cited by 79 - Related articles - All 9 versions
T Yoshida, S Yamagishi, K Nakamura, T … - Diabetologia, 2006 - Springer Page 1. SHORT COMMUNICATION Telmisartan inhibits AGE-induced C-reactive
protein production through downregulation of the receptor ... Cited by 33 - Related articles - BL Direct - All 5 versions
S Rahbar, R Natarajan, KK Yerneni, S Scott, … - Clinica Chimica Acta, 2000 - Elsevier Enhanced formation and accumulation of advanced glycation end products (AGEs)
have been proposed to play a major role in the pathogenesis of diabetic
complications, and atherosclerosis, leading to the development of a range ... Cited by 67 - Related articles - All 3 versions
KCB Tan, SWM Shiu, WS Chow, L Leng, R … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis Activation of the receptor for advanced glycation end
products (RAGE, also known as AGE- specific receptor [AGER]) has been implicated
in the development of diabetic vascular complications. Blockade of RAGE ... Cited by 39 - Related articles - All 5 versions
- ►ahajournals.org [PDF] C Cuccurullo, A Iezzi, ML Fazia, D De Cesare, … - Arteriosclerosis, thrombosis, and vascular biology, 2006 - Am Heart Assoc Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone:
410-528-4050. Permissions: Permissions & Rights Desk, Lippincott Williams &
Wilkins, a division of Wolters ... Suppression of Rage as a Basis of ... Cited by 40 - Related articles - All 9 versions
- ►endojournals.org MT Coughlan, V Thallas-Bonke, J Pete, DM … - Endocrinology, 2007 - Endocrine Soc Blockade of advanced glycation end product (AGE) accumulation with alagebrium
with concomitant angiotensin converting enzyme inhibition was tested for effects
on renal function and on other postulated mediators of diabetic renal ... Cited by 27 - Related articles - BL Direct - All 3 versions
S Yamagishi, M Takeuchi, T Matsui, K … - FEBS letters, 2005 - Elsevier Advanced glycation end product (AGE)-their receptor (RAGE) and angiotensin II
(AII) are implicated in diabetic retinopathy. However, a crosstalk between the
two is not fully understood. In vivo, AGE injection stimulated RAGE ... Cited by 28 - Related articles - All 5 versions
